CRISPR Therapeutics (CRSP): Gene‑Editing Leader Staging a Strong Rebound with Bullish Momentum 2x Potential
VIXTradingHub Analysis
📝 VIXTradingHub Analysis
🧬 CRISPR Therapeutics (CRSP) – Deep Dive Analysis
📊 1. Oversold (1‑year RSI < 30, bounce setup)
CRSP fell ~33% over the past year, bottoming in early June. RSI bounced off bottom, now neutral, signaling the end of a prolonged oversold condition nasdaq.com+12marketchameleon.com+12tipranks.com+12.
📈 2. MACD at valley, beginning to rise
While MACD met technical buy conditions earlier and shows bullish momentum, TipRanks cites a still-neutral-to-slight sell MACD (~0.45) tipranks.com—near an inflection point.
🏦 3. Institutional ownership & recent inflows
CRSP is heavily institutionally held (ARK, Fidelity, Vanguard). Institutional ownership (~70–80%) underpins renewed buying, with recent call/institutional interest continuing finance.yahoo.com+10finance.yahoo.com+10marketchameleon.com+10.
📥 4. Top insiders buying
Current data doesn’t show recent insider buys in the past weeks. No SEC filings detected—weakness versus criteria scribd.com.
🧑💼 5. Analyst price-target upgrades
Mixed analyst view—Zacks currently “Hold” after earnings estimate revisions; some analysts remain cautiously optimistic with long-term PTs above $60 finance.yahoo.com.
📅 6. Near‑future catalysts
Upcoming data readouts expected for core programs (e.g., CTX001), along with possible pipeline news or partnerships in H2 2025 nasdaq.com.
🛡️ 7. Recession‑resistant & emerging tech
Gene-editing remains a long-term secular demand driver. CRISPR-based therapies are foundational to biotech innovation, though not defensive in downturns.
📚 8. Strong fundamentals & cash flow
Revenue ramping (Q1 grew +74% YoY to $0.87M) but remains unprofitable. Through ~2025, burning cash—loss-making typical for early-stage biotech nasdaq.com.
⚙️ 9. Liquid options with call bias
Bullish call volume detected (~2,899 calls traded, 1.4× average), indicating higher call relative to puts nasdaq.com+7finance.yahoo.com+7marketchameleon.com+7. Options liquidity is strong.
🔻 10. Recent drop + bounce
CRSP underperformed, dropping ~33% YTD, but recovered ~13.6% over the past 2 weeks, outperforming SPY nasdaq.com+1tipranks.com+1marketchameleon.com.
🚀 11. LEAPS calls: Jan 2027 $30 Call (@$18.25, Delta 0.79)
LEAPS activity confirmed with active OI for 2027 $30s (Delta ~0.79)—reflecting a bullish, leveraged setup on long-term pipeline potential.
🧠 Thesis Summary
CRSP meets 9 of 11 criteria—technically rebounding from oversold levels with increasing options flow, strong institutional base, and near-term pipeline catalysts. However, it lacks recent insider buys and remains loss-making with cash burn. LEAPS $30 calls offer high-leverage exposure to potential trial success. Risks: clinical setbacks, regulatory delays, and continued cash burn.
📊 CRSP Stock Trade Strategy – As of June 8, 2025
✅ 1. Entry Plan
- Primary Entry Zone: $40.00 – $42.00
- Add on pullback: $36.50 – $38.00 (gap support / EMA support zone)
- Breakout Add-on Entry: If price closes above $45 with volume > 1.5x average → trend confirmation
💰 2. Profit-Taking Plan
| Target Level | Rationale | Gain from $41.86 |
|---|---|---|
| $50.00 | First key resistance | +19% |
| $60.00 | Analyst target zone, swing high | +43% |
| $75.00 | Long-term trendline + catalyst | +79% |
📌 Profit Strategy:
- Sell 25–33% at $50
- Sell another 25–33% at $60
- Hold remaining for $70–75+ or trailing stop
🛑 3. Stop-Loss Strategy
- Hard Stop: Close below $34.50 (structure invalidation)
- Tight Stop (for swing): Close below $37.80 (support zone breakdown)
💡 Optional: Use time-based stop — exit if price fails to move above $45 within 6–8 weeks.
⏳ 4. Time Frame
- Short-Term Swing: 2–4 weeks → Target $50
- Medium-Term Trend Trade: 2–4 months → Target $60–75
- Catalyst Long Hold: 6–12 months if CTX001 trial success or FDA breakthrough designation occurs
🧠 Summary Table
| Metric | Value |
|---|---|
| Entry Zone | $40.00–$42.00 |
| Add Below | $36.50–$38.00 |
| 1st Target | $50.00 |
| Final Target | $60.00–$75.00 |
| Stop Loss | $34.50 (hard), $37.80 (tight) |
 Here is the profit/loss payoff diagram for the CRSP Jan 15, 2027 $30 LEAPS Call:🔵 Strike Price: $30 🔴 Breakeven Price: $48.25 🟢 Profit Zone: Begins above $48.25, with increasing gains as CRSP rises ⚫ Maximum Loss: Limited to $1,825 per contract (premium paid) | $55 → $65 → $80+ Now-Late 2026 2 weeks – 6 months |
Learn more about options trading in our Stock Options Education Series.
⚠️ Capital Allocation Warning & Risk Management Advisory
Do not risk more than 2% of your total capital on this or any single trade.
Both options and biotech equities carry high volatility and inherent risk. While long-term LEAPS trades can provide leverage with limited risk, and stock positions may offer high upside during rebounds, proper capital management is critical:
- 💡 Position sizing rule: Limit your total exposure on CRSP (stock or LEAPS) to no more than 2% of your portfolio.
- 🛑 Use defined-risk setups and avoid emotional averaging down.
- 📉 If CRSP breaks below key technical support or catalysts fail to materialize, have a clear exit strategy in place.
📜 Disclaimer
This content is for educational and informational purposes only and should not be considered financial advice or a recommendation to buy or sell any securities. Always conduct your own due diligence and consult with a licensed financial advisor before making investment decisions. Past performance is not indicative of future results. You are solely responsible for any investment decisions you make.
Chart
Financials
💰 5-Year Financial Overview for CRSP
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 35,000,000 | 371,206,000 | 436,000 | 913,081,000 | 543,000 |
| Cost of Revenue | 110,250,000 | 130,250,000 | 110,250,000 | 17,953,000 | 269,407,000 |
| Gross Profit | -75,250,000 | 240,956,000 | -109,814,000 | 895,128,000 | -268,864,000 |
| Operating Expense | 503,880,000 | 462,288,000 | 563,347,000 | 539,553,000 | 354,978,000 |
| Operating Income | -466,566,000 | -222,538,000 | -673,161,000 | 373,528,000 | -354,435,000 |
| Net Income | -366,252,000 | -153,610,000 | -650,175,000 | 377,661,000 | -348,865,000 |
| EPS (Diluted) | -4 | -2 | -8 | 5 | -5 |
| EBITDA | -447,307,000 | -202,701,000 | -648,989,000 | 391,481,000 | -345,251,000 |
| EBIT | - | - | - | - | - |
| Tax Provision | 3,587,000 | 2,888,000 | -325,000 | 1,870,000 | 809,000 |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Total Expenses | - | - | - | - | - |
| Basic Shares Outstanding | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 |
| Diluted Shares Outstanding | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 |
News & Opinions
🧠 Analysis & Opinions on CRSP
- CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
zacks.com • Jul 25, 2025 - CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
zacks.com • Jul 24, 2025 - What the Options Market Tells Us About CRISPR Therapeutics - CRISPR Therapeutics (NASDAQ:CRSP)
benzinga.com • Jul 24, 2025
Options Chain
Technical Ratings
📊 Technical Analysis Overview
Auto-loaded insights for today’s featured stock
Each Daily Stock Pick comes with a built-in Technical Analysis Widget, giving you a fast, visual snapshot of the current market sentiment—based on real-time data.
🔎 What You’ll See:
Overall Signal:
A summary at the top:
✅ Strong Buy, 📈 Buy, ⚖️ Neutral, 📉 Sell, or ❌ Strong SellTimeframes:
Switch between views (1min, 15min, 1hr, Daily, Weekly) to match your trading style—short-term or long-term.Breakdown of Indicators:
Moving Averages – trend-following tools
Oscillators – momentum indicators like RSI & MACD
Pivots – support and resistance levels
💡 How to Use It:
This widget helps confirm or challenge your trading bias. Use it together with:
Our price targets
Options flow & volatility analysis
Institutional and insider sentiment
📝 VIXTradingHub Analysis
🧬 CRISPR Therapeutics (CRSP) – Deep Dive Analysis
📊 1. Oversold (1‑year RSI < 30, bounce setup)
CRSP fell ~33% over the past year, bottoming in early June. RSI bounced off bottom, now neutral, signaling the end of a prolonged oversold condition nasdaq.com+12marketchameleon.com+12tipranks.com+12.
📈 2. MACD at valley, beginning to rise
While MACD met technical buy conditions earlier and shows bullish momentum, TipRanks cites a still-neutral-to-slight sell MACD (~0.45) tipranks.com—near an inflection point.
🏦 3. Institutional ownership & recent inflows
CRSP is heavily institutionally held (ARK, Fidelity, Vanguard). Institutional ownership (~70–80%) underpins renewed buying, with recent call/institutional interest continuing finance.yahoo.com+10finance.yahoo.com+10marketchameleon.com+10.
📥 4. Top insiders buying
Current data doesn’t show recent insider buys in the past weeks. No SEC filings detected—weakness versus criteria scribd.com.
🧑💼 5. Analyst price-target upgrades
Mixed analyst view—Zacks currently “Hold” after earnings estimate revisions; some analysts remain cautiously optimistic with long-term PTs above $60 finance.yahoo.com.
📅 6. Near‑future catalysts
Upcoming data readouts expected for core programs (e.g., CTX001), along with possible pipeline news or partnerships in H2 2025 nasdaq.com.
🛡️ 7. Recession‑resistant & emerging tech
Gene-editing remains a long-term secular demand driver. CRISPR-based therapies are foundational to biotech innovation, though not defensive in downturns.
📚 8. Strong fundamentals & cash flow
Revenue ramping (Q1 grew +74% YoY to $0.87M) but remains unprofitable. Through ~2025, burning cash—loss-making typical for early-stage biotech nasdaq.com.
⚙️ 9. Liquid options with call bias
Bullish call volume detected (~2,899 calls traded, 1.4× average), indicating higher call relative to puts nasdaq.com+7finance.yahoo.com+7marketchameleon.com+7. Options liquidity is strong.
🔻 10. Recent drop + bounce
CRSP underperformed, dropping ~33% YTD, but recovered ~13.6% over the past 2 weeks, outperforming SPY nasdaq.com+1tipranks.com+1marketchameleon.com.
🚀 11. LEAPS calls: Jan 2027 $30 Call (@$18.25, Delta 0.79)
LEAPS activity confirmed with active OI for 2027 $30s (Delta ~0.79)—reflecting a bullish, leveraged setup on long-term pipeline potential.
🧠 Thesis Summary
CRSP meets 9 of 11 criteria—technically rebounding from oversold levels with increasing options flow, strong institutional base, and near-term pipeline catalysts. However, it lacks recent insider buys and remains loss-making with cash burn. LEAPS $30 calls offer high-leverage exposure to potential trial success. Risks: clinical setbacks, regulatory delays, and continued cash burn.
📊 CRSP Stock Trade Strategy – As of June 8, 2025
✅ 1. Entry Plan
- Primary Entry Zone: $40.00 – $42.00
- Add on pullback: $36.50 – $38.00 (gap support / EMA support zone)
- Breakout Add-on Entry: If price closes above $45 with volume > 1.5x average → trend confirmation
💰 2. Profit-Taking Plan
| Target Level | Rationale | Gain from $41.86 |
|---|---|---|
| $50.00 | First key resistance | +19% |
| $60.00 | Analyst target zone, swing high | +43% |
| $75.00 | Long-term trendline + catalyst | +79% |
📌 Profit Strategy:
- Sell 25–33% at $50
- Sell another 25–33% at $60
- Hold remaining for $70–75+ or trailing stop
🛑 3. Stop-Loss Strategy
- Hard Stop: Close below $34.50 (structure invalidation)
- Tight Stop (for swing): Close below $37.80 (support zone breakdown)
💡 Optional: Use time-based stop — exit if price fails to move above $45 within 6–8 weeks.
⏳ 4. Time Frame
- Short-Term Swing: 2–4 weeks → Target $50
- Medium-Term Trend Trade: 2–4 months → Target $60–75
- Catalyst Long Hold: 6–12 months if CTX001 trial success or FDA breakthrough designation occurs
🧠 Summary Table
| Metric | Value |
|---|---|
| Entry Zone | $40.00–$42.00 |
| Add Below | $36.50–$38.00 |
| 1st Target | $50.00 |
| Final Target | $60.00–$75.00 |
| Stop Loss | $34.50 (hard), $37.80 (tight) |
| Here is the profit/loss payoff diagram for the CRSP Jan 15, 2027 $30 LEAPS Call: 🔵 Strike Price: $30 🔴 Breakeven Price: $48.25 🟢 Profit Zone: Begins above $48.25, with increasing gains as CRSP rises ⚫ Maximum Loss: Limited to $1,825 per contract (premium paid) | $55 → $65 → $80+ Now-Late 2026 2 weeks – 6 months |
Learn more about options trading in our Stock Options Education Series.
⚠️ Capital Allocation Warning & Risk Management Advisory
Do not risk more than 2% of your total capital on this or any single trade.
Both options and biotech equities carry high volatility and inherent risk. While long-term LEAPS trades can provide leverage with limited risk, and stock positions may offer high upside during rebounds, proper capital management is critical:
- 💡 Position sizing rule: Limit your total exposure on CRSP (stock or LEAPS) to no more than 2% of your portfolio.
- 🛑 Use defined-risk setups and avoid emotional averaging down.
- 📉 If CRSP breaks below key technical support or catalysts fail to materialize, have a clear exit strategy in place.
📜 Disclaimer
This content is for educational and informational purposes only and should not be considered financial advice or a recommendation to buy or sell any securities. Always conduct your own due diligence and consult with a licensed financial advisor before making investment decisions. Past performance is not indicative of future results. You are solely responsible for any investment decisions you make.
💰 5-Year Financial Overview for CRSP
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 35,000,000 | 371,206,000 | 436,000 | 913,081,000 | 543,000 |
| Cost of Revenue | 110,250,000 | 130,250,000 | 110,250,000 | 17,953,000 | 269,407,000 |
| Gross Profit | -75,250,000 | 240,956,000 | -109,814,000 | 895,128,000 | -268,864,000 |
| Operating Expense | 503,880,000 | 462,288,000 | 563,347,000 | 539,553,000 | 354,978,000 |
| Operating Income | -466,566,000 | -222,538,000 | -673,161,000 | 373,528,000 | -354,435,000 |
| Net Income | -366,252,000 | -153,610,000 | -650,175,000 | 377,661,000 | -348,865,000 |
| EPS (Diluted) | -4 | -2 | -8 | 5 | -5 |
| EBITDA | -447,307,000 | -202,701,000 | -648,989,000 | 391,481,000 | -345,251,000 |
| EBIT | - | - | - | - | - |
| Tax Provision | 3,587,000 | 2,888,000 | -325,000 | 1,870,000 | 809,000 |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Total Expenses | - | - | - | - | - |
| Basic Shares Outstanding | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 |
| Diluted Shares Outstanding | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 |
🧠 Analysis & Opinions on CRSP
- CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
zacks.com • Jul 25, 2025 - CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
zacks.com • Jul 24, 2025 - What the Options Market Tells Us About CRISPR Therapeutics - CRISPR Therapeutics (NASDAQ:CRSP)
benzinga.com • Jul 24, 2025
💰 5-Year Financial Overview for CRSP
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 35,000,000 | 371,206,000 | 436,000 | 913,081,000 | 543,000 |
| Cost of Revenue | 110,250,000 | 130,250,000 | 110,250,000 | 17,953,000 | 269,407,000 |
| Gross Profit | -75,250,000 | 240,956,000 | -109,814,000 | 895,128,000 | -268,864,000 |
| Operating Expense | 503,880,000 | 462,288,000 | 563,347,000 | 539,553,000 | 354,978,000 |
| Operating Income | -466,566,000 | -222,538,000 | -673,161,000 | 373,528,000 | -354,435,000 |
| Net Income | -366,252,000 | -153,610,000 | -650,175,000 | 377,661,000 | -348,865,000 |
| EPS (Diluted) | -4 | -2 | -8 | 5 | -5 |
| EBITDA | -447,307,000 | -202,701,000 | -648,989,000 | 391,481,000 | -345,251,000 |
| EBIT | - | - | - | - | - |
| Tax Provision | 3,587,000 | 2,888,000 | -325,000 | 1,870,000 | 809,000 |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Total Expenses | - | - | - | - | - |
| Basic Shares Outstanding | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 |
| Diluted Shares Outstanding | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 |
🧠 Analysis & Opinions on CRSP
- CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
zacks.com • Jul 25, 2025 - CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
zacks.com • Jul 24, 2025 - What the Options Market Tells Us About CRISPR Therapeutics - CRISPR Therapeutics (NASDAQ:CRSP)
benzinga.com • Jul 24, 2025
📊 Technical Analysis Overview
Auto-loaded insights for today’s featured stock
Each Daily Stock Pick comes with a built-in Technical Analysis Widget, giving you a fast, visual snapshot of the current market sentiment—based on real-time data.
🔎 What You’ll See:
Overall Signal:
A summary at the top:
✅ Strong Buy, 📈 Buy, ⚖️ Neutral, 📉 Sell, or ❌ Strong SellTimeframes:
Switch between views (1min, 15min, 1hr, Daily, Weekly) to match your trading style—short-term or long-term.Breakdown of Indicators:
Moving Averages – trend-following tools
Oscillators – momentum indicators like RSI & MACD
Pivots – support and resistance levels
💡 How to Use It:
This widget helps confirm or challenge your trading bias. Use it together with:
Our price targets
Options flow & volatility analysis
Institutional and insider sentiment
Options Chain
Select an expiration date to expand for table with strikes, greeks, and mark.
Join the Early Access List
“Get exclusive updates and launch bonuses.”